Telix Acquires ITM Isotope in $1.65B Deal to Challenge Novartis in Radiopharma

Key points

• Telix will pay $1.65 billion upfront to acquire ITM Isotope Technologies Munich.
• Additional payments of up to $700 million are tied to regulatory approvals and sales milestones for ITM-11.
• ITM-11, a radioligand therapy for neuroendocrine tumors, was rejected by the FDA in August 2026 due to manufacturing and controls issues.
• The merger combines Telix’s pipeline, including TLX591, with ITM’s supply network for lutetium-177, a key isotope used in cancer therapies.
• William Blair analysts described the combined entity as having 'extremely bullish' future growth prospects.

Background

This acquisition follows the FDA’s rejection of ITM-11 in August 2026, which cited chemistry, manufacturing, and controls issues at a third-party facility. Earlier reports indicated that ITM-11 showed promising clinical data, with progression-free survival of 23.9 months compared to 14.1 months for the standard treatment everolimus. The deal positions the combined company to compete directly with Novartis, which dominates the radiopharmaceutical space with products like Lutathera and Pluvicto.

How outlets are covering it

Fierce Biotech emphasizes the strategic value of ITM’s manufacturing network and the potential for ITM-11 to accelerate Telix’s entry into the therapeutic market, noting CEO Christian Behrenbruch’s confidence in resubmitting the drug after addressing FDA concerns. STAT highlights the broader industry context, framing the merger as a move to create a well-resourced competitor to Novartis in a field that has seen rapid growth since 2018. While both sources agree on the deal’s financial structure, Fierce Biotech provides more detail on the specific milestone payments, whereas STAT focuses on the competitive dynamics and the surprise nature of the FDA rejection.

Why it matters

The merger creates a significant player in the radiopharmaceutical market, challenging Novartis’s dominance. The combined entity will have enhanced manufacturing capabilities and a stronger pipeline, including ITM-11 and TLX591, which could impact treatment options for neuroendocrine and prostate cancers. The deal also underscores the importance of regulatory compliance in the radiopharma sector, as the FDA’s rejection of ITM-11 highlights the risks associated with manufacturing issues.

What to watch

Telix and ITM must resolve the FDA’s concerns regarding ITM-11’s manufacturing, with a resubmission or agreement on the path forward required for the deal to close. Investors will watch for progress in ITM-11’s regulatory approval and the combined company’s ability to integrate ITM’s supply network. The success of the merger will depend on the timely approval of ITM-11 and the achievement of sales milestones, which could trigger additional payments of up to $700 million.